Arrival & check-in
15:00-15:15	Welcome     [Kinnear Centre 203]
15:15-16:15	EBPS Equity, Diversity, and Inclusion Panel     [Kinnear Centre 203] “Global EDI/DEI” Moderator: Karen Szumlinski (University of California at Santa Barbara) Shelly Flagel (University of Michigan) Oritoke Okeowo (Federal University of Technology, Aukre, Nigeria) Gill Bedi (University of Melbourne, Melbourne, VIC, Australia)
16:15-17:30	Travel Awardee Data Blitz     [Kinnear Centre 203] Moderator: Connor Haggarty (Wayne State University)
17:30-18:00	Mentor-Mentee Meetup     [Kinnear Centre 203]
18:00-19:30	Welcome Reception     [Kinnear Centre 101] (Dinner on own)

7:15-8:30	Breakfast     [Kinnear Centre 203 - foyer] (Thursday poster presenters put up posters)
8:30-9:30	Keynote Lecture 1     [Kinnear Centre 203] David Nutt (Imperial College London, London, UK) Psychedelics for addictions – from neuroscience to clinical trials
9:30-10:45	Symposia • Psilocybin     [Kinnear Centre 203] Chair: Harriet de Wit, University of Chicago 9:30 Melissa Herman (University of North Carolina, Chapel Hill, NC, USA) Psilocin impacts on neuronal activity and behavior in stress-sensitive brain circuitry 9:55 Marcus Meinhardt (Central Institute of Mental Health, Mannheim, Germany) Psychedelics in psychiatry: Hope or Hype? Insights from preclinical animal models with a focus on AUD 10:20 Fred Barrett (Johns Hopkins University, Baltimore, MD, USA) Psilocybin for the treatment of substance use and mood disorders
10:45-11:05	Break & poster viewing     [Foyer/Kinnear Centre 201] (Thursday presenters: make sure your posters are up!)
11:05-12:15	Perspectives Panel • Psychedelics     [Kinnear Centre 203] Charting a path forward Moderator: Leah Mayo, University of Calgary Alaina Jaster (Wayne State University, MI, USA) Gill Bedi (University of Melbourne, Melbourne, VIC, Australia) Neşe Devenot (Johns Hopkins University, Baltimore, MD, USA)
12:15	Lunch     [Vistas dining room] (including hosted roundtables by EBPS EDI committee) Poster viewing     [Kinnear Centre 201]
13:30-14:45	Symposia • Ketamine     [Kinnear Centre 203] Chair: Leah Mayo, University of Calgary 13:30 Argel Aguilar-Valles (Carleton University, Canada) Decoding ketamine: receptor interactions and mRNA translation 13:55 Zoë Hughes (Gilgamesh Pharmaceuticals, NY, USA) GM-1020: a novel orally bioavailable NMDA receptor antagonist showing preclinical efficacy and better tolerability than ketamine 14:20 Celia Morgan (University of Exeter, Exeter, UK) Ketamine adjunctive to psychological therapy as a treatment for alcohol use disorder: mechanisms and methods
14:45-15:45	Keynote Lecture 2     [Kinnear Centre 203] Alex Kwan (Cornell University, Ithaca, NY, USA) Psychedelic drug action on neural circuits
15:45-16:15	Break & poster viewing     [Foyer/Kinnear Centre 201]
16:15-17:15	Hot topics     [Kinnear Centre 203] Moderator: Ryann Tansey, University of Calgary 16:15 Harpreet Kaur (PharmAla Biotech, Canada) APA-01: Development of potent entactogen with improved safety pharmacology compared to MDMA 16:30 Sarah Gibson Cook (University of Calgary, Canada) Acute effects of psilocybin on the HPA axis 16:45 Margarita Moreno (University of Almeria, Spain) 5HT2A vs GRIN1 receptor as possible targets to reduce compulsive behavior in a preclinical model of male Wistar rats 17:00 Paola Palombo (Federal University of Sao Paulo, Brazil) Mindfulness-based relapse prevention (MBRP): Promising therapeutic adjuvant in adherence and permanence of patients diagnosed with substance use disorder in prolonged Brazilian hospitalizations
17:15-18:45	Poster session 1 and social     [Kinnear Centre 201] Thursday presenters should be at their posters
	Dinner on own

7:15-8:30	Breakfast     [Kinnear Centre 203 - foyer] (Friday poster presenters put up posters)
8:30-9:30	Keynote Lecture 3     [Kinnear Centre 203] Margaret Haney (Columbia University, New York, NY, USA) Development of novel pharmacotherapeutic interventions for treating Cannabis Use Disorder
9:30-10:45	Symposia • Cannabinoids     [Kinnear Centre 203] Chair: Matthew Hill, University of Calgary 9:30 Sachin Patel (Northwestern University, Chicago, IL, USA) Endocannabinoid modulation of stress resilience, anxiety, and alcohol withdrawal-associated behaviors 9:55 Francis Lee (Weill Cornell Medical School, New York, NY, USA) Role of the endocannabinoid 2-AG in regulating opioid reward 10:20 Ziva Cooper (UCLA, CA, USA) Associations between circulating endocannabinoids and dose-dependent reinforcing and analgesic effects of cannabis in humans: results from a double-blind placebo-controlled study
10:45-11:05	Break & poster viewing     [Foyer/Kinnear Centre 201] Friday presenters: make sure your posters are up!
11:05-12:15	Perspectives panel • Unpacking Myths, Fears, and Facts about Drug Policy: Lessons from North America     [Kinnear Centre 203] Moderator: Matthew Hill, University of Calgary Rebecca Haines-Saah (University of Calgary, Calgary, Alberta, Canada) Manisha Krishnan (Emmy-award winning journalist)
12:15	Lunch     [Vistas dining room] (including hosted roundtables by EBPS EDI committee) Poster viewing     [Kinnear Centre 201]
13:30-14:45	Symposia • Orexin     [Kinnear Centre 203] Chair: Stephanie Borgland (University of Calgary) 13:30 Brooke Schmeichel (East Tennesse State University, Johnson City, TN, USA) Behavior and brainwaves: hypocretin's role in addiction and sleep dysfunction explored through rodent research 13:55 Michel Steiner (Idorsia Pharmaceuticals, Allschwil, Switzerland) Examining orexin receptor antagonists for their abuse liability and therapeutic potential in substance use disorders 14:20 Kelly Dunn (Johns Hopkins University, Baltimore, MD, USA) Innovations for opioid withdrawal management
14:45-15:45	Keynote Lecture 4     [Kinnear Centre 203] Lorenzo Leggio (National Institutes of Health, Baltimore, MD, USA) Mind the gut: developing new treatments for alcohol use disorder
15:45-16:00	Break & poster viewing     [Foyer/Kinnear Centre 201]
16:00-17:00	Hot topics     [Kinnear Centre 203] Moderator: Gavin Petrie (University of Calgary) 16:15 Renata Marchette (National Institute on Drug Abuse, US) Understanding poly-drug overdoses in a rat model 16:30 Loren Wilkinson (University of Chicago, US) Exploring the role of cholinergic signaling and α7 expressing GLP-1 neurons in cocaine reward 16:45 Laura Ornelas (University of New Mexico, US) Predator odor, stress reactivity, and the endocannabinoid system 17:00 Marc Ferger (University of Cologne, Germany) Endocannabinoids in adolescents with non-suicidal self-injury: Diagnostic, prognostic and risk biomarker potential?
17:00-17:15	Closing     [Kinnear Centre 203]
17:15-18:45	Poster session 2 and social     [Kinnear Centre 201] Friday presenters should be at their posters

When preparing your poster, please remember that its maximum size is 45 x 45 inches. Note that the orientation is landscape, not portrait.

Correct format...    Wrong format...

Posters should be put up in the morning, no later than the morning break, and taken down at the end of each poster session.

• Session 1 A
• Session 2 B

• Thursday, 26 September

  P.1 Oritoke Okeowo (Akure, Nigeria)
  Protective role of glucosamine against behavioral deficits, neural perturbations, and hepatorenal dysfunctions in a rat model of unpredictable chronic mild stress

  P.2 Christian Faig (Edmonton, AB, Canada)
  Modulation of nociception and pain related behaviours by cingulate projecting claustrum cells

  P.3 Erica Ramirez (Irvine, CA, USA)
  Reunited and it feels so good: how ventral pallidal GABA neurons modulate social behaviors

  P.4 Naru Kang (Baltimore, MD, USA)
  The impact of autism spectrum disorder models on motivated social interactions

  P.5 Shannon Lopez (Santa Barbara, CA, USA)
  A subchronic history of concurrent binge-drinking does not modify the impact of social isolation on glutamate-related protein expression in mature adult mice

  P.6 Kimberly Papastrat (Baltimore, MD, USA)
  A socio-sensory mechanism buffering drug craving

  P.7 Seetha Krishnan (Cudahy, WI, USA)
  Drug-place association learning paradigms in head-fixed mice navigating virtual reality contexts

  P.8 Milan Valyear (Montréal, QC, Canada)
  A novel pharmacotherapeutic approach to disengage consummatory behaviour

  P.9 Tyler Allen (Durham, NH, USA)
  Role of the corticostriatal pathway in learning with interoceptive nicotine stimulus

  P.10 Anita Sikic (Guelph, ON, Canada)
  Interoceptive and preliminary proteomic effects of nicotine vs cigarette smoke extract in male and female rats

  P.11 Mustafa Ali (La Jolla, CA, USA)
  Effects of the phosphodiesterase 10A inhibitor AMG579 on alcohol self-administration in post-chronic intermittent ethanol exposed rats

  P.12 Karen Szumlinski (Santa Barbara, CA, USA)
  PPDE4B regulates the cross-sensitization between binge-eating and -drinking in a novel mouse model of disease co-morbidity

  P.13 Marlaina Stocco (Santa Barbara, CA, USA)
  Reinforcement interval modulates the choice between methamphetamine and food reinforcement in male and female rats

  P.14 Rita Fuchs (Pullman, WA, USA)
  Corticotropin-releasing factor circuit regulates cocaine-memory reconsolidation in rats

  P.15 Fernando Cano (Santa Barbara, CA, USA)
  Expression of incubated craving for methamphetamine and sucrose are dissociated from mTOR activity

  P.16 Laura Huerta Sanchez (Santa Barbara, CA, USA)
  Sex differences in incubated cocaine-craving following inhibition of NMDA-type glutamate receptors within the prelimbic cortex

  P.17 Stefanie Todesco (Vancouver, BC, Canada)
  Approach-bias retraining intervention effects on stimulant-related memory associations among inpatients with a primary stimulant use disorder

  P.18 Uma Chatterjee (Madison, WI, USA)
  MDMA-AT, PTSD, & Comorbid OCD: a systematic review of the potential effects of 3,4-methylenedioxymethamphetamine-assisted therapy for PTSD on comorbid OCD

  P.19 Ana Deutsch (Calgary, AB, Canada)
  Acute effects of methamphetamine and MDMA on peripheral endocannabinoid levels in healthy adults

  P.20 Faiz Kassim (Linköping, Sweden)
  Acute caffeine administration impaired spatial working memory in habitual coffee/tea drinkers: a preliminary randomized, double-blind study

  P.21 Niloofar Mirzadzare (Calgary, AB, Canada)
  Investigating the effects of ketamine on sleep quality and quantity

  P.22 Arghavan Nepton (Ottawa, ON, Canada)
  Investigating the mechanisms of action of ketamine in depression: personality traits, genetic polymorphisms, and epigenetic changes in serotonergic and glutaminergic pathways

  P.23 Lily Aleksandrova (Vancouver, BC, Canada)
  Synaptic plasticity, ketamine, and classical psychedelics: what are the connections?

  P.24 Delong Zhou (Montréal, QC, Canada)
  Profiling the psilocybin-induced transcriptional response in mouse medial prefrontal cortex

  P.25 Melanie Lysenko-Martin (Vancouver, BC, Canada)
  Impacts of various doses of psilocybin, and M100,907 serotonin 2A antagonist, on rodent gambling behaviours

  P.26 Megan Greener (Nottingham, United Kingdom)
  Exploring the role of dopamine-and-cAMP-regulated phosphoprotein, Mr 32kDa (DARPP-32) in addiction: a full systems biology approach

  P.27 Margarita Moreno (Almeria, Spain)
  5HT2A vs GRIN1 receptor as possible targets to reduce compulsive behavior in a preclinical model of male Wistar rats

  P.28 Peter Facchini (Calgary, AB, Canada)
  Semi-systematic series of indolethylamine derivatives reveals that hallucination is not required for positive behavioural outcomes in mice

  P.29 Sean Goldy (Baltimore, MD, USA)
  Risks and benefits between recreational psychedelics and cannabis

  P.30 Luis Contreras (Calgary, AB, Canada)
  A preliminary exploration into the motivations for participating in a psilocybin for alcohol use disorder trial

  P.31 Brendan Leier (Edmonton, AB, Canada)
  A Gestalt theory of psychedelic experience

  P.32 Sarah Kratina (Calgary, AB, Canada)
  Mechanisms supporting psilocybin-assisted psychotherapy for alcohol use disorder: protocol for a randomized, controlled clinical trial   

  P.33 Ashley Ethier (Calgary, AB, Canada)
  Addiction recovery in higher education:  a pilot study exploring student experiences

  P.34 Paola Palombo (São Paulo, Brazil)
  Mindfulness-based relapse prevention (MBRP): promising therapeutic adjuvant in adherence and permanence of patients diagnosed with substance use disorder (SUD) in prolonged Brazilian hospitalizations

  P.35 Sarah Mina (Calgary, AB, Canada)
  Effects of elevated anandamide via FAAH inhibition on amygdala and vmPFC functional connectivity in adults with PTSD

• Friday, 27 September

  P.35 Agata Cieslik-Starkiewicz (Krakow, Poland)
  Trait pessimism determines the intensity of alcohol drinking in rats – behavioral and biochemical correlates

  P.36 Jason Hensley (Durham, NH, USA)
  Individual differences in ethanol seeking: Integrating behavioral economics and neurobiological markers of cue-induced reinstatement

  P.37 Alexia dos Anjos Santos (São Paulo, Brazil)
  Proteomic changes associated with context-induced ethanol-seeking in the ventral hippocampus

  P.38 Cristiane Aparecida Favoretto (La Jolla, CA, USA)
  Impacts of chronic intermittent ethanol vapor and predator odor on ethanol intake and striatal D1 and CB1 cannabinoid receptor-expressing medium spiny neurons

  P.39 Catharine Mielnik (Toronto, ON, Canada)
  The bidirectional effect of 2-AG on hyperdopaminergic states: implications of the CB2 receptor.

  P.40 Hakan Kayir (London, ON, Canada)
  THCV dose-dependently blocks or substitutes for THC in a drug discrimination task in rats

  P.41 Anoo Maskeri (Minneapolis, MN, USA)
  Evaluating initial cannabinoid response and reward-seeking as predictors of cannabinoid seeking in heterogeneous stock rats

  P.42 Catherine Hume (Calgary, Alberta, Canada)
  Investigating the appetitive and motivational effects of vaporised tetrahydrocannabinol (THC) 

  P.43 Craig Amadio (Waterloo, ON, Canada)
  The effects of vapourized cannabis extract on working memory

  P.44 Camila Saenz (Calgary, AB, Canada)
  Sex differences in the effects of maternal cannabis consumption on the metabolic outcomes of high fat diet in adult offspring

  P.45 Jessica Scheufen (Calgary, AB, Canada)
  The effects of vaporized cannabis on adolescent neurodevelopment

  P.46 Alaina Jaster (Detroit, MI, USA)
  Endocannabinoid markers of familial risk for depression among adolescents

  P.47 Keira Aubin (Calgary, AB, Canada)
  Exploring the relationship between early-life trauma, endocannabinoid system dysregulation, and problematic cannabis use among young adults

  P.48 Samantha Ely (Detroit, MI, USA)
  Plasma endocannabinoid concentrations in adolescents with lifetime suicide attempt: a preliminary case-control study

  P.49 Abigail Lunge (Calgary, AB, Canada)
  Exploring the relationship between kynurenine pathway metabolites, endocannabinoids, and inflammatory markers to histories of childhood maltreatment and substance use disorders  

  P.50 Lars Östman Vasko (Linköping, Sweden)
  The impact of childhood maltreatment and substance use disorder on inflammation and kynurenine metabolites during stress

  P.51 Ryann Tansey (Calgary, AB, Canada)
  Acute alcohol intake, peripheral 2-arachidonylglycerol concentrations, and functional connectivity of the anterior insula: A single-blind, within-subjects experiment

  P.52 Cecilia Bergeria (Baltimore, MD, USA)
  Evaluation of the pharmacokinetic and pharmacodynamic profile of acute oral cannabigerol (CBG) in human subjects

  P.53 Gavin Petrie (Calgary, AB, Canada)
  Effect of concurrent FAAH inhibition and prolonged exposure therapy on symptomology in people diagnosed with post-traumatic stress disorder

  P.54 Connor Haggarty (Detroit, MI, USA)
  Cannabis as a pharmacotherapeutic: beliefs of cannabis users and service providers

  P.55 Karina Thiessen (Vancouver, BC, Canada)
  A protocol for a double-blind randomized placebo-controlled crossover fMRI trial examining the effects of cannabis on acute stress response

  P.56 Robert LeComte (Baltimore, MD, USA)
  Steeper delay discounting profiles evident in persons who have low sensitivity to opioids

  P.57 Sara Kroll (Zurich, Switzerland)
  The role of the endocannabinoid system in social stress reactivity among chronic non-medical prescription opioid users

  P.58 Greer McKendrick (Baltimore, MD, USA)
  Subjective opioid detection diverges from objective and analgesic responses 

  P.59 Justin Strickland (Baltimore, MD, USA)
  Association of xylazine exposure with opioid withdrawal symptoms in a clinical setting

  P.60 Jessica Karlovcec (Guelph, ON, Canada)
  Investigation of the generalization of morphine-elicited interoceptive effects to other opioids in rats

  P.61 Renata Marchette (Baltimore, MD, USA)
  Understanding poly-drug overdoses in a rat model

  P.62 Lauren Brown (Nottingham, United Kingdom)
  An assessment of mu-opioid receptor reserve on opioid-related behaviours using the pseudo-irreversible antagonist methocinnamox

  P.63 Aida Mohammadkhani (Calgary, AB, Canada)
  Effects of chronic morphine on LH orexin and dynorphin modulation of VTA dopamine neurons

  P.64 Soyon Ahn (Vancouver, BC, Canada)
  TGIR reverses hypodopaminergia in the nucleus accumbens of rats repeatedly exposed to fentanyl

  P.65 Catherine Moore (Baltimore, MD, USA)
  Effects of benzylideneoxymorphine (BOM), a bifunctional opioid receptor ligand, on alcohol seeking and self-administration in baboons

  P.66 Fiona Choi (Vancouver, BC, Canada)
  A randomized placebo-controlled study of a botanical formulation (TGIR) in healthy volunteers

  P.67 Daria Merrikh (Calgary, AB, Canada)
  Repetitive transcranial magnetic stimulation (rTMS) as a treatment for attention deficit hyperactivity disorder (ADHD): a systematic review 

  P.68 Vivian Ngo (Hamilton, ON, Canada)
  The emerging role of GLP-1 receptor agonists in substance use disorders and other psychiatric disorders: a systematic review